celecoxib has been researched along with phenazopyridine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
Ayubi, E; Kamali, K; Nabizadeh, M; Nikbakht, J; Sarhadi, S | 1 |
1 trial(s) available for celecoxib and phenazopyridine
Article | Year |
---|---|
Comparison of the Efficacy of Oxybutynin, Phenazopyridine, Celecoxib, and Placebo in the Treatment of Urinary Tract Symptoms after BCG Therapy in Patients with Bladder Tumors.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Celecoxib; Female; Humans; Male; Mandelic Acids; Middle Aged; Phenazopyridine; Urinary Bladder Neoplasms; Urinary Tract | 2020 |
1 other study(ies) available for celecoxib and phenazopyridine
Article | Year |
---|---|
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |